CaroSpir, a Liquid Form of Spironolactone, Now Available in Unit Dose Cups
The new packaging allows for ease of administration and convenience.
Cardiovascular Disease
FDA Unable to Approve Narsoplimab for HSCT-TMA Without More Data
Narsoplimab is a human monoclonal antibody that specifically targets mannan-binding lectin-associated serine protease-2.
Lower BP Affects CVD Event Risk in Adults With Hypertension and LVH
While health benefits of intensive blood pressure lowering have been observed in people at high risk for CVD, researchers sought to examine its effects in patients with hypertension and LVH.
USPSTF: Starting Aspirin in Patients 60 or Older for Primary CVD Prevention Not Recommended
Starting aspirin in patients 60 years or older to prevent a first heart attack or stroke is not recommended.
FDA Approves Change in Contraindications for Optison
The removal of the contraindication to screen for hypersensitivity to blood and blood products is expected to improve workflow efficiency for health care professionals.
AHA Scientific Statement Addresses Weight Loss Strategies for Hypertension Prevention and Treatment
The American Heart Association released a scientific statement reviewing weight loss strategies for the prevention and treatment of hypertension.
FDA: Risk of LAAO Implant-Related Adverse Events May Be Higher for Women
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
Study Shows Similar Safety Profile With Rivaroxaban vs ASA After Fontan Procedure
The phase 3 UNIVERSE study evaluated rivaroxaban oral suspension in patients aged 2 to 8 years with single ventricle physiology who had the Fontan procedure.
Study Evaluating Ampreloxetine for Neurogenic Orthostatic Hypotension Misses Endpoint
The phase 3 study was evaluating the efficacy and safety of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients 30 years of age and older.
Empagliflozin Gets Breakthrough Tx Status for Heart Failure With Preserved Ejection Fraction
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
- Loading...
Loading...
Loading... 
Loading...